WallStreetZenWallStreetZen

NASDAQ: MDGL
Madrigal Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MDGL

Based on 5 analysts offering 12 month price targets for Madrigal Pharmaceuticals Inc

Min Forecast
$428.00-2.25%
Avg Forecast
$490.00+11.91%
Max Forecast
$554.00+26.53%

Should I buy or sell MDGL stock?

Based on 5 analysts offering ratings for Madrigal Pharmaceuticals Inc.

Strong Buy
Strong Buy
4 analysts 80%
Buy
1 analysts 20%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MDGL's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MDGL as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their MDGL stock forecasts and price targets.

MDGL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-26
lockedlocked$00.00+00.00%2025-08-20
lockedlocked$00.00+00.00%2025-08-12
lockedlocked$00.00+00.00%2025-08-06Find Out Why
lockedlocked$00.00+00.00%2025-05-02Find Out Why

1 of 1

Forecast return on equity

Is MDGL forecast to generate an efficient return?

Company
116.51%
Industry
122.1%
Market
-51.71%
MDGL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MDGL forecast to generate an efficient return on assets?

Company
79.86%
Industry
45.93%
MDGL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MDGL earnings per share forecast

What is MDGL's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$8.65
Avg 2 year Forecast
$3.14
Avg 3 year Forecast
$21.30

MDGL revenue forecast

What is MDGL's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$839.4M+62.81%
Avg 2 year Forecast
$1.3B+149.39%
Avg 3 year Forecast
$1.9B+265.3%
MDGL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MDGL revenue growth forecast

How is MDGL forecast to perform vs Biotechnology companies and vs the US market?

Company
53.32%
Industry
83.25%
Market
10.49%
MDGL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MDGL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MDGL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MDGL$437.85$490.00+11.91%Strong Buy
BBIO$51.76$64.64+24.89%Strong Buy
EXEL$37.42$46.43+24.08%Buy
MRNA$24.09$33.22+37.91%Hold
VRNA$105.91$120.44+13.72%Buy
View Top Biotech Stocks

Madrigal Pharmaceuticals Stock Forecast FAQ

Is Madrigal Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: MDGL) stock is to Strong Buy MDGL stock.

Out of 5 analysts, 4 (80%) are recommending MDGL as a Strong Buy, 1 (20%) are recommending MDGL as a Buy, 0 (0%) are recommending MDGL as a Hold, 0 (0%) are recommending MDGL as a Sell, and 0 (0%) are recommending MDGL as a Strong Sell.

If you're new to stock investing, here's how to buy Madrigal Pharmaceuticals stock.

What is MDGL's earnings growth forecast for 2025-2027?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.8%.

Madrigal Pharmaceuticals's earnings in 2025 is -$281,899,000.On average, 8 Wall Street analysts forecast MDGL's earnings for 2025 to be -$192,799,971, with the lowest MDGL earnings forecast at -$330,546,078, and the highest MDGL earnings forecast at -$126,378,709. On average, 8 Wall Street analysts forecast MDGL's earnings for 2026 to be $69,876,059, with the lowest MDGL earnings forecast at -$153,794,197, and the highest MDGL earnings forecast at $284,184,929.

In 2027, MDGL is forecast to generate $474,666,842 in earnings, with the lowest earnings forecast at $207,956,501 and the highest earnings forecast at $770,308,324.

What is MDGL's revenue growth forecast for 2025-2027?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's forecast annual revenue growth rate of 53.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.49%.

Madrigal Pharmaceuticals's revenue in 2025 is $515,547,000.On average, 5 Wall Street analysts forecast MDGL's revenue for 2025 to be $18,708,595,947, with the lowest MDGL revenue forecast at $15,334,841,632, and the highest MDGL revenue forecast at $19,970,956,544. On average, 5 Wall Street analysts forecast MDGL's revenue for 2026 to be $28,657,921,438, with the lowest MDGL revenue forecast at $25,654,655,114, and the highest MDGL revenue forecast at $30,094,180,923.

In 2027, MDGL is forecast to generate $41,976,944,644 in revenue, with the lowest revenue forecast at $36,311,032,707 and the highest revenue forecast at $44,874,471,886.

What is MDGL's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MDGL) forecast ROA is 79.86%, which is higher than the forecast US Biotechnology industry average of 45.93%.

What is MDGL's Price Target?

According to 5 Wall Street analysts that have issued a 1 year MDGL price target, the average MDGL price target is $490.00, with the highest MDGL stock price forecast at $554.00 and the lowest MDGL stock price forecast at $428.00.

On average, Wall Street analysts predict that Madrigal Pharmaceuticals's share price could reach $490.00 by Aug 26, 2026. The average Madrigal Pharmaceuticals stock price prediction forecasts a potential upside of 11.91% from the current MDGL share price of $437.85.

What is MDGL's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's current Earnings Per Share (EPS) is -$12.73. On average, analysts forecast that MDGL's EPS will be -$8.65 for 2025, with the lowest EPS forecast at -$14.83, and the highest EPS forecast at -$5.67. On average, analysts forecast that MDGL's EPS will be $3.14 for 2026, with the lowest EPS forecast at -$6.90, and the highest EPS forecast at $12.75. In 2027, MDGL's EPS is forecast to hit $21.30 (min: $9.33, max: $34.56).

What is MDGL's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MDGL) forecast ROE is 116.51%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.